| Revenue growth | FY26: 37.1% YoY (₹2053.1cr); Q4FY26: 134.9% YoY (₹788.7cr). |
|---|---|
| Margins | EBITDA margin expanded to 29.4% in FY26 (up 650 bps). |
| Order book | Growth in new project orders for current and next FY. |
| Demand visibility | Strong visibility in short to medium term for commercial molecules. |
| Management confidence | High; citing good business visibility and strong note ending FY26. |
Growth
FY26 Revenue grew 37.1% to ₹2,053.1cr; PAT surged 40% to ₹363.1cr. Q4FY26 EBITDA margin reached 40.5%.
Outlook
Investing in Peptide manufacturing and a new R&D center; FY26 Capex outflow was ₹397cr.
Risks
Specialty segment remains subdued due to specific molecule performance; working capital and inventory fluctuations noted.
Earnings Call filed with NSE, NSE: NEULANDLAB. Summary written with AI assistance from the document.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹21,905.00
- Market cap
- ₹28,104 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 56.5×Sector 47.4×
- Promoter holding
- 32.62%-0.01% QoQ
- FII holding
- 21.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Production Started
Neuland commissioned its first commercial peptide manufacturing module with 7,000L reactor capacity. Module two expansion is underway to meet rising customer demand for peptide APIs.
- peptide manufacturing reactor capacity
- 7000 L
Neuland Laboratories Capacity Expansion: ₹126 Cr Investment
Neuland Laboratories' board approved ₹126 Crore capex to acquire 134 acres of land in Andhra Pradesh for future expansion. The company holds ROFR on additional land.
- Value
- ₹126.0 Cr
- land acquisition
- 134.0 acres
Neuland Laboratories Credit Rating
Neuland Laboratories announced that CRISIL Ratings has reaffirmed its long-term credit rating at CRISIL A+/Positive and its short-term rating at CRISIL A1.
Neuland Laboratories Capital Structure Change
Malabar India Fund Limited sold 2,72,634 equity shares of Neuland Laboratories Ltd via open market. This transaction reduces their stake from 7.18% to 5.06%.
Neuland Laboratories Business Update
Neuland Laboratories announced the completion of a US FDA inspection at its Unit 3 facility. The regulator issued a Form 483 with one procedural observation.
Neuland Laboratories Earnings Call Transcript: Key Takeaways
Q1FY27 was broadly in line with expectations, showing strong YoY revenue and profit growth. Management remains confident in achieving a 20% growth rate despite inherent quarterly volatility in the CMS business.
- Call
- Guides 20% growth